Loading...
01/10 15:46
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals mixed signals. Basic financial performance shows some decline in gross profit and margin, but EPS grew slightly. Product development is hindered by slower-than-expected recovery in Infant Formula. Market strategy shows potential with new SKUs, though facing execution challenges. Expenses are managed well, but tariffs are a concern. The shareholder return plan remains stable. Q&A highlights management's unclear responses on critical issues, adding uncertainty. Overall, the sentiment is neutral, with no significant catalysts or detractors to drive the stock price significantly in either direction.
Organic net sales (Q3 2025) Declined 4.4%, impacted by 1.6% from global OTC business due to soft OTC category consumption and 2.8% from businesses under review (Oral Care and Infant Formula).
Gross profit and margin (Q3 2025) Gross profit was $417 million, down $30 million year-over-year. Gross margin declined 110 basis points due to lower net sales, divestitures, and exited products.
Operating profit and margin (Q3 2025) Operating profit was $173 million, down 4.9% year-over-year due to lower net sales flow-through and higher operating expenses in Infant Formula. Partially offset by benefits from Project Energize and cost management.
Earnings per share (EPS) (Q3 2025) $0.80, up $0.01 versus the prior year, driven by cost management and operational improvements.
Year-to-date organic net sales (2025) Declined 1.7%, driven by 0.8% from businesses under review and 0.5% from absence of last year's Opill launch stocking benefits.
Year-to-date gross and operating margins (2025) Expanded, with organic operating income growing 13% due to accretive initiatives, Infant Formula recovery, and cost management.
Year-to-date EPS (2025) Grew 21% (27% organically) to $1.97, driven by operational improvements and cost management.
Project Energize Generated $163 million in gross annual savings, above the midpoint of the $140 million to $170 million range.
Supply chain reinvention On track to deliver $150 million to $200 million in benefits by the end of 2025.
Infant Formula business (Q3 2025) Stabilized operationally, but store brand share recovery is slower than expected, contributing to a $100 million impact on net sales.
Infant Formula: Stabilized operationally but store brand share recovery is slower than expected. Strategic review announced to assess its long-term role within Perrigo's portfolio. Investment of $240 million paused.
OTC Products: Perrigo's U.S. OTC store brand gained volume share for 6 consecutive months, driven by strong execution, consumer trade from national brands, and new distribution. In Europe, key brands like ellaOne and Jungle Formula gained dollar share for 5 consecutive months.
U.S. OTC Market: Perrigo outperformed despite a challenging market, gaining 90 basis points in volume share over 13 weeks in categories like smoking cessation, allergy, and women's health.
European OTC Market: Despite a decline in total OTC euro consumption, Perrigo's key brands gained dollar share for 5 consecutive months, driven by focused A&P investments and targeted activation strategies.
Supply Chain Reinvention: On track to deliver $150 million to $200 million in benefits by the end of 2025.
Project Energize: Generated $163 million in gross annual savings, exceeding the midpoint of the $140 million to $170 million range.
Portfolio Streamlining: Sale of Dermacosmetics business on track to close in Q1 2026. Strategic reviews of Infant Formula and Oral Care businesses are ongoing.
Leadership and Innovation: New leadership team in place, scaling brand-building capabilities, and implementing a commercial growth model to enhance efficiency and market reach.
Soft OTC category consumption trends: Both U.S. and European OTC markets are experiencing softer-than-expected consumption trends, leading to a decline in net sales and impacting financial performance.
Infant Formula business challenges: The recovery of store brand share in the Infant Formula segment is slower than anticipated, compounded by the loss of Good Start brand distribution. This has resulted in a $100 million impact on the 2025 net sales outlook.
Strategic review of Infant Formula and Oral Care businesses: The company is conducting strategic reviews of these businesses, which may require sustained investment and management focus, potentially diverting resources from core operations.
Supply chain reinvention and cost management pressures: While the supply chain reinvention project is on track, achieving the targeted $150-$200 million in benefits requires continued focus and execution, posing operational risks.
Market consumption unpredictability: Year-to-date consumption trends in consumer health have been dynamic and unpredictable, with significant declines in the third quarter, creating challenges in forecasting and planning.
Gross margin pressures: Gross margins have declined due to lower net sales, divestitures, and a shift towards lower-margin store brands, impacting profitability.
Leverage and debt management: Updated financial outlook projects a higher year-end net debt to adjusted EBITDA ratio of 3.8x, above the prior target of 3.5x, due to revised net sales expectations.
Paused investment in Infant Formula: The previously announced $240 million investment in the Infant Formula business has been paused, reflecting uncertainties in its long-term strategic fit and external market conditions.
2025 Organic Net Sales Outlook: Revised to a decline of 2% to 2.5% due to softer-than-expected OTC category consumption in both the U.S. and Europe, as well as lower-than-anticipated Infant Formula share growth.
Gross Margin for 2025: Expected to be approximately 39% for the year.
Operating Margin for 2025: Reaffirmed at approximately 15% for the year, supported by benefits from accretive initiatives and prudent cost management.
2025 Earnings Per Share (EPS) Outlook: Updated to a range of $2.70 to $2.80, representing 5% to 9% growth versus 2024.
Infant Formula Business Strategic Review: The company is assessing the long-term role of the Infant Formula business within its portfolio, considering a full range of options and pausing the previously announced $240 million investment.
Dermacosmetics Divestiture: On track to close in the first quarter of 2026, with proceeds expected to support deleveraging goals.
Oral Care Business Strategic Review: The strategic review of the Oral Care business is ongoing.
Q4 2025 Organic Growth Expectations: Global OTC business expected to grow approximately flat to 1%, while Nutrition category sales are expected to decline year-over-year due to lower contract volumes and prior year restocking activity.
Q4 2025 Margins: Expected to be below prior year levels due to lower volumes and tariff-related costs.
Dividend Sustainability: The company remains committed to sustaining its dividend as part of its corporate priorities.
Dividend Returns: Year-to-date, Perrigo has returned $119 million to shareholders through dividends.
Share Repurchase Program: No mention of a share repurchase program was made during the call.
The earnings call reveals mixed signals. Basic financial performance shows some decline in gross profit and margin, but EPS grew slightly. Product development is hindered by slower-than-expected recovery in Infant Formula. Market strategy shows potential with new SKUs, though facing execution challenges. Expenses are managed well, but tariffs are a concern. The shareholder return plan remains stable. Q&A highlights management's unclear responses on critical issues, adding uncertainty. Overall, the sentiment is neutral, with no significant catalysts or detractors to drive the stock price significantly in either direction.
The earnings call summary and Q&A indicate a positive outlook. Despite a decline in gross profit and operating income, the company is optimistic about the second half, expecting a 25% revenue increase and high single-digit organic sales growth. The strategic pricing and retailer discussions are productive, and consumer trends favor private label products. While there are challenges, such as infant formula market volatility, the company's proactive measures and confidence in achieving its EPS target suggest a positive stock price movement.
The earnings call presents several challenges: increased tariffs impacting COGS, supply chain issues, and declining consumer confidence. Despite strong financial metrics like EPS and margin growth, the cautious consumer behavior and regulatory uncertainties weigh heavily. The Q&A reveals concerns about tariff impacts and unclear management responses. With no share buyback plan and a negative sentiment from analysts, the stock is likely to see a negative reaction. The lack of a clear market cap makes it difficult to assess volatility, but overall sentiment suggests a -2% to -8% movement.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
